Valneva to Present and Hold Investor Meetings at the Jefferies US Healthcare Conference
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and participate in 1-on-1 meetings with institutional investors at the Jefferies Healthcare Conference which will take place from June 8 to 10, 2022 in New York.
Valneva’s Chief Executive Officer Thomas Lingelbach and Chief Financial Officer Peter Bühler will notably discuss the Company’s late-stage vaccine candidates against Lyme disease (VLA15), chikungunya (VLA1553) and COVID-19 (VLA2001).
Valneva was recently granted Conditional Marketing Authorization in the United Kingdom for its inactivated COVID-19 vaccine candidate VLA2001 and filed a Marketing Authorization Application with the European Medicines in May 2022. The Company also recently commenced the pre-submission process with the US Food and Drug Administration for its single-shot chikungunya vaccine candidate VLA1553 after reporting final positive pivotal Phase 3 results and lot-to-lot data. Additionally, in April 2022, Valneva and its partner Pfizer reported first positive pediatric results for their Lyme disease vaccine candidate VLA15. These positive data build on the strong immunogenicity profile reported for adult participants (18-65 years old) in February 2022, and the two companies expect to proceed with a Phase 3 clinical trial in participants age 5-65, which is planned to start in the third quarter of 2022.
The fireside chat at the Jefferies conference will take place on June 9, 2022 at 11:30am EDT (17:30 CEST) and will be accessible live via the following link, https://wsw.com/webcast/jeff240/valn/1848225. A replay of the webcast will be available following the live events in the “Investor” section of the Valneva website at www.valneva.com.
To request a meeting at the event, please contact your representative at Jefferies.
About Valneva SE
Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The Company takes a highly specialized and targeted approach to vaccine development and then applies its deep understanding of vaccine science to develop prophylactic vaccines addressing these diseases. Valneva has leveraged its expertise and capabilities both to successfully commercialize two vaccines and to rapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, the chikungunya virus and COVID-19.
Valneva Investor and Media Contacts
VP, Global Communications and European Investor Relations
M +33 (0)6 4516 7099